Company logo

NRC - National Research Corporation

NASDAQ -> Healthcare -> Diagnostics & Research
Lincoln, United States
Type: Equity

NRC price evolution
NRC
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Jan 2024
Current assets
Cash $0.48 $1.7 $6.65
Short term investments
Net receivables $11.71 $10.06 $11.13 $12.38
Inventory
Total current assets $20.7 $16.95 $20.01 $24.36
Long term investments
Property, plant & equipment $36.32 $35.55 $33.47 $30.27
Goodwill & intangible assets $63.02 $63.05 $63.09
Total noncurrent assets $102.15 $100.9 $98.08
Total investments
Total assets $131.8 $119.1 $120.91 $122.44
Current liabilities
Accounts payable $2.59 $1.24 $2.4 $1.3
Deferred revenue $14.51 $15.19 $14.83
Short long term debt $16.57 $14.5 $7.21
Total current liabilities $44.28 $45.73 $48.85 $36.2
Long term debt $44.91 $25.66 $27.57 $29.47
Total noncurrent liabilities $33.17 $35.12 $37.28
Total debt $42.22 $42.07 $36.68
Total liabilities $97.17 $78.9 $83.97 $73.48
Shareholders' equity
Retained earnings -$20.86 -$23.73 -$27.04 -$30.53
Other shareholder equity
Total shareholder equity $40.2 $36.95 $48.95
(in millions $) 31 Jan 2024 31 Jan 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $6.65 $25.03 $54.36 $34.69
Short term investments
Net receivables $12.38 $15.3 $13.73 $13.92
Inventory
Total current assets $24.36 $43.72 $73.71 $54.11
Long term investments
Property, plant & equipment $30.27 $17.8 $13.37 $13.03
Goodwill & intangible assets $63.09 $63.23 $63.4 $58.66
Total noncurrent assets $98.08 $86.75 $83.83 $79.31
Total investments
Total assets $122.44 $130.46 $157.54 $133.42
Current liabilities
Accounts payable $1.3 $1.15 $1.94 $1.09
Deferred revenue $14.83 $15.2 $17.21 $15.59
Short long term debt $7.21 $4.49 $4.28 $4.06
Total current liabilities $36.2 $33.42 $40.39 $31.68
Long term debt $29.47 $17.73 $22.27 $26.55
Total noncurrent liabilities $37.28 $25.01 $31.82 $37.43
Total debt $36.68 $22.18 $26.55 $30.61
Total liabilities $73.48 $58.43 $72.2 $69.11
Shareholders' equity
Retained earnings -$30.53 -$25.18 -$36.11 -$61.38
Other shareholder equity -$2.38 -$2.4
Total shareholder equity $48.95 $72.03 $85.34 $64.31
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Jan 2024
Revenue
Total revenue $35.82 $35.02 $35.31
Cost of revenue $13.42 $13.86
Gross Profit $20.51 $21.6 $21.46
Operating activities
Research & development
Selling, general & administrative $11.22 $11.25
Total operating expenses $12.53 $12.73 $12.7
Operating income $8.87 $8.76
Income from continuing operations
EBIT $8.88 $8.8
Income tax expense $1.61 $2.15 $1.83
Interest expense -$0.67 $0.56 $0.6
Net income
Net income $5.69 $6.17 $6.36
Income (for common shares) $6.17 $6.36
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Revenue
Total revenue $148.58 $151.57 $147.95 $133.28
Cost of revenue $56.02 $57.05 $52.35 $49.19
Gross Profit $92.56 $94.52 $95.6 $84.09
Operating activities
Research & development
Selling, general & administrative $46.62 $42.7 $38.96 $34.44
Total operating expenses $52.52 $47.98 $45.33 $41.41
Operating income $40.05 $46.54 $50.27 $42.68
Income from continuing operations
EBIT $40.82 $44.02 $50.29 $43.28
Income tax expense $8.99 $11.02 $11.15 $4.21
Interest expense $0.86 $1.21 $1.67 $1.81
Net income
Net income $30.97 $31.8 $37.47 $37.26
Income (for common shares) $30.97 $31.8 $37.47 $37.26
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Net income $6.17 $6.36 $8.86
Operating activities
Depreciation $1.51 $1.45 $1.43
Business acquisitions & disposals
Stock-based compensation -$0.06 -$0.04 $0.26
Total cash flows from operations $6.79 $12.04 $11.71
Investing activities
Capital expenditures -$5.27 -$4.14 -$3.77
Investments
Total cash flows from investing -$15.84 -$5.27 -$4.14 -$3.77
Financing activities
Dividends paid -$8.64 -$2.87 -$2.91 -$2.95
Sale and purchase of stock -$15 -$15
Net borrowings $0.14 $5.37 $12.83
Total cash flows from financing -$15.6 -$2.73 -$12.85 -$5.11
Effect of exchange rate -$0 $0 -$0
Change in cash and equivalents -$3.19 -$1.21 -$4.95 $2.83
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income $30.97 $31.8 $37.47 $37.26
Operating activities
Depreciation $5.9 $5.28 $6.37 $7.5
Business acquisitions & disposals -$3
Stock-based compensation $0.94 $1.2 $0.62 $0.68
Total cash flows from operations $38.11 $36.27 $46.34 $40.64
Investing activities
Capital expenditures -$15.78 -$9.84 -$5.51 -$3.98
Investments
Total cash flows from investing -$15.78 -$9.84 -$8.51 -$3.72
Financing activities
Dividends paid -$36.37 -$20.96 -$9.16 -$10.52
Sale and purchase of stock -$18.52 -$27.62 -$3.7 $1.73
Net borrowings $14.17 -$4.87 -$4.59 -$3.94
Total cash flows from financing -$40.71 -$55.58 -$18.16 -$15.5
Effect of exchange rate -$0 -$0.18 $0 -$0.24
Change in cash and equivalents -$18.37 -$29.34 $19.67 $21.17
News
National Research's Q4 Earnings Drop Y/Y, Stock Falls 9%
Zacks · via Yahoo Finance 30 Jan 2025
National Research Corporation (NASDAQ:NRC) is a favorite amongst institutional...
Simply Wall St. · via Yahoo Finance 13 Jan 2025
National Research (NASDAQ:NRC) Has Affirmed Its Dividend Of $0.12
Simply Wall St. · via Yahoo Finance 3 Dec 2024
NRC Health unveils AI-enabled healthcare solutions
Hospital Management · via Yahoo Finance 1 Sep 2024
National Research (NASDAQ:NRC) Will Pay A Dividend Of $0.12
Simply Wall St. via Yahoo Finance 11 May 2024
National Research Corporation (NASDAQ:NRC) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance 10 May 2024
Investors in National Research (NASDAQ:NRC) have unfortunately lost 5.2% over...
Simply Wall St. · via Yahoo Finance 19 Mar 2024
National Research (NASDAQ:NRC) Is Paying Out A Dividend Of $0.12
Simply Wall St. via Yahoo Finance 17 Feb 2024
National Research Corporation (NASDAQ:NRC) Q4 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance 15 Feb 2024
With 50% institutional ownership, National Research Corporation (NASDAQ:NRC) is a favorite amongst...
Simply Wall St. via Yahoo Finance 21 Jan 2024
Fundamentals
Market cap $280.77M
Enterprise value N/A
Shares outstanding 23.48M
Revenue N/A
EBITDA N/A
EBIT N/A
Net Income N/A
Revenue Q/Q -5.60%
Revenue Y/Y N/A
P/E ratio N/A
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio N/A
P/B ratio N/A
Book/Share N/A
Cash/Share N/A
EPS N/A
ROA N/A
ROE N/A
Debt/Equity 1.50
Net debt/EBITDA N/A
Current ratio 0.47
Quick ratio N/A